Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (BOLERO-4)
An Open-label, Phase II, Single-arm Study of Everolimus in Combination With Letrozole in the Treatment of Postmenopausal Women With Estrogen Receptor Positive HER2 Negative Metastatic or Locally Advanced Breast Cancer
Sponsor: Novartis Pharmaceuticals
This PHASE2 trial investigates Hormone Receptor Positive Breast Cancer and is currently completed. Novartis Pharmaceuticals leads this study, which shows 31 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
31 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Mar 2022 — Jun 2023 [monthly]
Completed PHASE2
▶ Show 26 earlier versions
-
May 2021 — Mar 2022 [monthly]
Completed PHASE2
-
Apr 2021 — May 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Sep 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE2
-
Aug 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE2
-
Jul 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE2
-
May 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE2
-
Apr 2020 — May 2020 [monthly]
Active Not Recruiting PHASE2
-
Mar 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE2
-
Jan 2020 — Mar 2020 [monthly]
Active Not Recruiting PHASE2
-
Dec 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE2
-
Nov 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE2
-
Aug 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE2
-
Jan 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
-
Oct 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Aug 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2017 — Aug 2017 [monthly]
Recruiting PHASE2
-
Jun 2017 — Jul 2017 [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
-
Mar 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Mar 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .